Sorafenib News and Research

RSS
Sorafenib (Nexavar) is an oral multikinase inhibitor for the treatment of two common types of cancer, hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC).
U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

U.S. approval of Nexavar (sorafenib) for inoperable liver cancer

Cancer trial combines multiple drugs to attack blood vessel formation in patients with kidney cancer

Cancer trial combines multiple drugs to attack blood vessel formation in patients with kidney cancer

Axitinib shows promise for patients with advanced kidney cancer

Axitinib shows promise for patients with advanced kidney cancer

Interferon alpha and sorafenib combined work better than either alone against kidney cancer

Interferon alpha and sorafenib combined work better than either alone against kidney cancer

Researchers identify new combination therapy that promotes cancer cell death

Researchers identify new combination therapy that promotes cancer cell death

Scientists take exciting approach for attacking cancers

Scientists take exciting approach for attacking cancers

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer and Onyx submit supplemental NDA for Nexavar

New molecular mechanism discovered that may 'spontaneously' cause liver cancer

New molecular mechanism discovered that may 'spontaneously' cause liver cancer

Researchers find new mechanism of action of the anti-cancer drug sorafenib

Researchers find new mechanism of action of the anti-cancer drug sorafenib

Results of phase II studies of pazopanib

Results of phase II studies of pazopanib

Liver cancer drug Nexavar, a major breakthrough

Liver cancer drug Nexavar, a major breakthrough

FDA approves Torisel (temsirolimus) for advanced kidney cancer

FDA approves Torisel (temsirolimus) for advanced kidney cancer

Nexavar approved in Europe for treatment of advanced kidney cancer

Nexavar approved in Europe for treatment of advanced kidney cancer

New treatment for chronic eosinophilic leukemia

New treatment for chronic eosinophilic leukemia

Therapy for metastatic renal cell carcinoma remains inadequate

Therapy for metastatic renal cell carcinoma remains inadequate

Targeted cancer therapies: Another step forward

Targeted cancer therapies: Another step forward

Targeted cancer therapies: Another step forward

Targeted cancer therapies: Another step forward

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer